SCHEMBL22492017

SCHEMBL22492017

CN1C(=O)CCC(C(=O)O)C1c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.67
MEN1 O00255 4/20 0.67
POLB P06746 1/20 0.65
HTT P42858 1/20 0.62
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
SRD5A1 P18405 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 2/20 0.42
CYP3A4 P08684 1/20 0.42
THRB P10828 1/20 0.42
TSHR P16473 1/20 0.42
THPO P40225 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ACE P12821 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B2 P37059 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22831278 1.00 KMT2A (0.67) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL22831282 1.00 KMT2A (0.67) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL11475285 0.87 TDP1 (0.61) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL11479651 0.87 KMT2A (0.51) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL11478087 0.85 MDM2 (0.51) KMT2AMEN1POLBHTTTSHR
SCHEMBL11477376 0.84 KMT2A (0.71) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL10685501 0.84 LMNA (0.58) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL11483073 0.83 KMT2A (0.53) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL21056614 0.81 KMT2A (0.76) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL7821256 0.79 KMT2A (0.47) KMT2AMEN1POLBHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 LES LABORATOIRES SERVIER (FR) 2022-05-17 US disclosed
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 LES LABORATOIRES SERVIER (FR) 2020-12-31 US disclosed
EP-3717482-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Les Laboratoires Servier SAS (FR) 2020-10-07 EP disclosed
CN-111542524-A Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 法国施维雅药厂 2020-08-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 USP7, PSMA7, PSMB7 KMT2A 815/4885MEN1 3508/4885POLB 1500/4885
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 PSMB7, PSMA7, USP7 KMT2A 1046/4885MEN1 4052/4885POLB 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.